Other languages ViroGates A/S

Equities

VIRO

DK0061030574

Market Closed - Nasdaq Copenhagen Other stock markets 15:59:52 26/04/2024 BST			5-day change	1st Jan Change
6.5 ^DKK	-11.92%		+8.33%	+7.97%

04-15	Virogates A/S Announces the Outcome of Its Q-Submission Filing for Sobi®? Turbi Latex with the Us Food and Drug Administration	CI
03-21	ViroGates A/S Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Virogates A/S Announces the Outcome of Its Q-Submission Filing for Sobi®? Turbi Latex with the Us Food and Drug Administration	04-15
ViroGates A/S Reports Earnings Results for the Full Year Ended December 31, 2023	03-21
ViroGates A/S Provides Earnings Guidance for the Year 2024	12-21
ViroGates A/S Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09
ViroGates A/S Announces Positive Results from a Randomized Controlled Clinical Trial on Supar-Guided Antibody Treatment in Sepsis	22/09/23
ViroGates A/S Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	17/08/23
Virogates Provides Earnings Guidance for 2023	17/08/23
ViroGates A/S Announces an Agreement with Sobi for the Development of Suparnostic®	02/06/23
ViroGates A/S Reports Earnings Results for the First Quarter Ended March 31, 2023	04/05/23
ViroGates A/S Announces the Commercial Launch of suPARnostic POC+ Product	24/02/23
ViroGates A/S Announces CE-IVD approval for suPARnostic® TurbiLatex on the Roche Diagnostics cobas® Pure and Pro instrument platforms	06/02/23
ViroGates A/S Revises Earnings Guidance for Full-Year 2022 and 2023	16/12/22
ViroGates A/S Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	10/11/22
ViroGates A/S Announces the Publication of A New Study That Shows SsuPAR upar Causes Cardiovascular Disease	05/10/22
ViroGates announces CE-IVD approval for suPARnostic® TurbiLatex on the Beckman Coulter AU5800 platform	23/09/22
ViroGates A/S Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	18/08/22
ViroGates A/S Provides Revenue Guidance for the Year 2022 and 2023	22/06/22
ViroGates A/S Announces Board Changes	30/05/22
ViroGates Announces the CE-Ivd Accreditation of Its Finger-Prick Blood-Testing Product, Suparnostic® Poc+	25/05/22
ViroGates A/S Reports Earnings Results for the First Quarter Ended March 31, 2022	04/05/22

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages ViroGates A/S

Equities

VIRO

DK0061030574

Other languages

Filters